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Background: The discovery of the chromosomal fusion product of anaplastic lymphoma kinase
(ALK) with echinoderm microtubule-associated protein-like 4 (EML4) (EML4-ALK) has changed
the treatment paradigm of lung cancer. In this study, we analysed the clinical characteristics,
including bronchoscopic findings, of patients with EML4-ALK-positive adenocarcinoma and
compared them with those of EGFR mutation-positive patients.
Materials and methods: In this retrospective cohort study, the clinical characteristics and
bronchoscopic findings of patients with ALK fusion-positive lung cancers were compared to pa-
tients with EGFR-mutant lung cancers.
Results: Among the 440 patients with adenocarcinoma of lung screened for this study, 46
(10.4%) harboured the EML4-ALK fusion, 90 (20.4%) harboured an activating EGFR mutation,
and all had adenocarcinoma. In univariate analysis, ALK-positive patients were significantly
younger than EGFR-positive patients (p Z 0.004) and were more commonly male
(p Z 0.021). An initial status of stage IV metastatic cancer was more frequently noted in
EML4-ALK-positive patients (p Z 0.012), with initial brain metastasis frequently observed
(p Z 0.007). Compared with EGFR-positive patients, EML4-ALK-positive patients were signifi-
cantly more likely to have positive bronchoscopic findings, which suggested a more centralizedt of Internal Medicine, Seoul National University Bundang Hospital, 173-82 Gumi-Ro, Bundang-Gu,
: þ82 31 787 7002; fax: þ82 31 787 4052.
.-T. Lee).
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Comparison of ALK- and EGFR-positive lung cancer 389origin (p Z 0.001). EML4-ALK patients also had significantly more positive bronchoscopic find-
ings and were more commonly male in multivariate analysis.
Conclusions: The EML4-ALK fusion defines a new molecular subset of NSCLC that has distinct
clinical and bronchoscopic findings suggesting more proximal origin when compared to tumours
harbouring EGFR mutations.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Lung cancer is a leading cause of cancer-related deaths
worldwide, with most patients being diagnosed in an
advanced stage of disease, when treatment is only pallia-
tive [1]. Although various cytotoxic chemotherapeutic
agents have been used to treat patients with lung cancer,
the prognosis of these patients remains unsatisfactory [2].
In the past several years, an increase in the under-
standing of the molecular basis of lung cancer, especially
non-small cell lung cancer (NSCLC) has led to a change in
the treatment of the disease [3]. Personalized cancer
therapy has attracted considerable attention as research
into the number of oncogenic molecules has grown and
specific molecular treatment strategies against these tar-
gets have been developed. For example, a subset of NSCLC
patients with mutations in the epidermal growth factor
receptor (EGFR) gene (EGFR-positive) have a higher
response rate when treated with EGFR tyrosine kinase in-
hibitors (TKIs) [3].
In 2007, the chromosomal fusion of anaplastic lymphoma
kinase (ALK) with echinoderm microtubule-associated pro-
tein-like 4 (EML4) was discovered by screening a retroviral,
complementary DNA expression library [4,5]. This fusion
results from an inversion within chromosome 2p, which
leads to expression of a chimeric tyrosine kinase in which
the N-terminal half of EML4 is fused to the intracellular
kinase domain of ALK [6].
Pharmacological approaches targeting ALK rearrange-
ments in patients with NSCLC have been successful thus
far, and encouraging results were recently observed with
the ALK inhibitor, crizotinib (PF-02341066; Pfizer, New
York, NY) [7]. Patients with advanced lung cancer, har-
bouring the EML4-ALK fusion (ALK-positive), and treated
with crizotinib showed a favourable treatment response in
a phase I trial [7]. Following the phase I dose escalation
study, 82 patients with advanced ALK-positive disease
were identified from 1500 NSCLC patients to receive cri-
zotinib treatment. The response rate of these patients
was 57% (47 of 82), and 27 patients (33%) maintained
stable disease. The high response rate and good safety
profile of crizotinib treatment among ALK-positive
patients have led to the initiation of phase III clinical
trials [7e9].
While previous study designs of targeted agents for a
specific genotype have focused on clinically enriched pop-
ulations, we are moving into an era where genotype is more
useful than clinical features in treatment, and clinical trials
focus on molecularly enriched populations.
Several studies have reported that ALK-positive patients
are younger and have never smoked [10,11]. Pathologically,EML4-ALK-positive tumours are predominately adenocarci-
nomas, and some tumours contain signet ring cells.
Patients with lung adenocarcinoma harbouring EGFR
mutation, another important oncogenic mutation, shared
similar clinical characteristics, such as female predomi-
nance, young age and no association with smoking [3].
Furthermore, EML4-ALK fusions and activating EGFR
mutations are mutually exclusive [11,12]. Although there is
valuable preliminary data concerning EML4-ALK-positive
tumours, previous studies have not provided precise infor-
mation on the clinical characteristics of EML4-ALK-positive
advanced NSCLCs. Moreover, there is little statistical power
associated with these previous studies because the cohorts
examined were small [13,14].
In previous studies, no comments on the phenotypes of
bronchoscopic findings in ALK-positive patients compared
with EGFR-positive patients were made. In this study, based
on the clinical overlap of the ALK-positive and EGFR-
positive adenocarcinoma subgroups, we analysed the clin-
ical characteristics, including bronchoscopic findings, of
patients with ALK-positive adenocarcinomas and compared
them with the characteristics of EGFR-positive patients.Study population and methods
Eligibility criteria
In this retrospective cohort study, we reviewed the clinical
characteristics and pathological specimens from 440 pa-
tients diagnosed with adenocarcinoma of lung who under-
went pathological confirmation at Seoul National University
Bundang Hospital from May 2003 to June 2011, consecu-
tively. Some of the patients overlapped with our previous
study [15]. Inclusion criteria for this study were as follows:
a diagnosis of pathologically confirmed adenocarcinoma;
complete analysis for EGFR mutations and ALK; and
completion of all diagnostic and staging procedures, such as
chest computed tomography (CT), positron emission
tomography-CT (PET-CT), bronchoscopy, brain magnetic
resonance imaging, percutaneous needle aspiration/biopsy,
and endobronchial ultrasound, if clinically required.
Tumour-node-metastasis (TNM) staging of the cancer was
evaluated using the seventh edition of the staging system of
International Association for the Study of Lung Cancer [16].
If patients received curative surgical resection, patholog-
ical staging was applied. If patients did not receive curative
surgical resection, the clinical staging was used for final
staging.
Smoking status was defined as never-smokers (<100
lifetime cigarettes) and smokers (current and ex-smokers).
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included age, sex, smoking history, tumour histology,
tumour size, surgical procedure, and metastasis status [7].
Immunohistochemistry and fluorescent in situ
hybridization for EML4-ALK fusion
Fluorescent in situ hybridization (FISH) for ALK is the
standard method for diagnosis of ALK fusion; however, we
used immunohistochemistry (IHC) to detect the ALK protein
and screen tumour samples for their EML4-ALK fusion status
because the frequency of ALK rearrangement is quite low,
and FISH is expensive. ALK was classified as negative when
either the IHC or the FISH result was negative [15,17]. We
used the ‘SNUBH EGFR/ALK protocol for analysis of the
EML4-ALK fusion [17]. For IHC of ALK, formalin-fixed,
paraffin-embedded tissues (FFPEs) were sectioned at a
thickness of 4 mm and stained with an antibody against ALK
(mouse monoclonal, clone 5A4, Novocastra, 1:30, New-
castle, UK) using a Ventana automated immunostainer
(Ventana Medical Systems, Tucson, AZ). IHC results for ALK
were scored, and a 0 or þ1 score in intensity indicated a
negative result for EML4-ALK fusion. If the IHC score for ALK
was þ2 or þ3, FISH for ALK was performed for confirmation.
The patient was classified as ALK-positive only when FISH
for ALK confirmed the EML4-ALK fusion [15].
EGFR mutation
To determine mutations within the EGFR gene, we ampli-
fied exons 18e21 of EGFR by reverse transcription poly-
merase chain reaction (RT-PCR) using a Qiagen OneStep RT-
PCR Kit (Qiagen, Hilden, Germany). The cycle conditions for
RT-PCR have been described previously [18].
Bronchoscopic findings
All patients underwent a bronchoscopic examination, per-
formed by expert pulmonologists using an Olympus EVIS
bronchovideoscope BF260 (Olympus, Tokyo, Japan). If no
significant endobronchial lesions were found in the most
distal bronchi that can be examined by bronchoscope, the
patient was classified as having ‘no endobronchial lesions’.
If a tumour mass or infiltration was visible through the
bronchoscope, the patient was classified as having a ‘visible
tumour’. If a secondary compression effect due to a tumour
was found, the patient was classified as having extrinsic
compression (Fig. 1).
Statistical analysis
To assess the clinico-pathological characteristics of lung
cancer patients harbouring the EML4-ALK fusion or EGFR
mutation, we applied either the Student’s t test or the
Fisher’s exact test, as appropriate. P values of <0.05 were
considered statistically significant. Multivariable analysis
was performed using the logistic regression procedure to
assess the relationship between the clinical characteristics
of ALK- and EGFR-positive patients. All statistical analyses
were performed with IBM SPSS software (version 19.0,
Chicago, IL, USA).This study was approved by the Institutional Regulatory
Board of Seoul National University Bundang Hospital (IRB B-
1207-164-101).
Results
Clinical characteristics of ALK- and EGFR-positive
patients
Among the 440 screened patients with adenocarcinoma of
lung, 46 (10.4%) patients harboured the EML4-ALK fusion
(ALK-positive) and 90 (20.4%) patients harboured an acti-
vating EGFR mutation (EGFR-positive). Patients without the
EGFR gene mutation or the EML4-ALK fusion were excluded
from the study due to possible heterogeneity of molecular
abnormalities such as mutations in K-ras, MET, or RET.
The clinical characteristics of the ALK- and EGFR-
positive patients are summarized in Table 1. As the me-
dian ages of the ALK-positive and EGFR-positive groups
were 52 and 64 years, respectively, patients in the ALK-
positive group were significantly younger (p Z 0.004).
Twenty-five (54.3%) of the ALK-positive patients were
women, compared to 67 (74.4%) of the EGFR-positive pa-
tients (p Z 0.021). Smoking status did not differ according
to gene status; 56.5% of ALK-positive patients and 56.7% of
EGFR-positive patients were never-smokers (p Z 1.000).
Initial staging of ALK- and EGFR-positive patients
TNM status of the cancer stage was compared between the
2 groups (Table 2). There were no differences in the tumour
status (T) (pZ 0.099) of the ALK-positive and EGFR-positive
patients; however, the node status (N) in the ALK-positive
group was more advanced than in the EGFR-positive group
(p Z 0.001). ALK-positive patients also had a higher M1a
and M1b metastasis status (M) (13 patients, 28.3%) than
EGFR-positive patients (9 patients, 10%) (pZ 0.003) (Table
2B).
Analysis of metastasis in ALK- and EGFR-positive
patients
Upon initial lung cancer diagnosis, 13 patients (28.3%) in
the ALK-positive group had metastases, compared with 9
patients (10%) in the EGFR-positive group (p Z 0.012)
(Table 3). In the ALK-positive group, 7 (15.2%) patients had
brain metastasis and 5 (10.9%) had lung metastasis. ALK-
positive patients had significantly higher proportions of
brain metastases at the time of diagnosis than EGFR-
positive patients (15.2% versus 2.2%, respectively,
p Z 0.007).
Bronchoscopic findings of ALK- and EGFR-positive
patients
In ALK-positive patients, 18 (39.1%) of the 46 patients had
positive bronchoscopic findings, including visible tumour
mass, infiltration, and extrinsic compression. Only 12
(13.3%) EGFR-positive patients showed positive broncho-
scopic lesions (Table 4). Interestingly, when compared with
Figure 1 Classification of bronchoscopic findings: Positive tumour findings.
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Table 1 Comparison of clinical characteristics of patients
according to EML4-ALK fusion and EGFR mutation status.
ALK (þ) EGFR (þ) p-Value
N Z 46 N Z 90
Median age in
years (range)
52 (27e78) 64 (28e80) 0.004
Gender 0.021
Male 21 (45.7%) 23 (25.6%)
Female 25 (54.3%) 67 (74.4%)
Smoking 1.000
Never-smoker 26 (56.5%) 51 (56.7%)
Current/Ex-smoker 20 (43.5%) 39 (43.3%)
Table 3 Metastasis analysis of ALK- and EGFR-positive
patients.
ALK þ EGFR þ p-Value
n Z 46 n Z 90
Initial metastasis 13 (28.3%) 9 (10%) 0.012
Lung 5 (10.9%) 6 (6.7%) 0.508
Brain 7 (15.2%) 2 (2.2%) 0.007
Adrenal 1 (2.2%) 0 (0%) 0.338
Bone 2 (4.3%) 1 (1.1%) 0.264
Lymph node 0 (0%) 0 (%) 1
Pleura 1 (2.2%) 0 (0%) 0.338
Liver 0 (0%) 0 (0%) 1
Pancreas 0 (0%) 0 (0%) 1
Kidney 0 (0%) 0 (0%) 1
Data are presented as n (%).
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cantly more likely to have positive bronchial lesions
(p Z 0.001). This finding strongly suggests that tumours
with EML4-ALK fusions occurred more proximally than
EGFR-mutated tumours, even though all tumours were
pathologically classified as adenocarcinomas.Table 2 Comparison of the initial TNM stage of tumours of
ALK- and EGFR-positive patients.
(A) Initial staging of patients’ tumours
Stage group T N M ALKþ EGFRþ
IA T1a,b N0 M0 8 (17.4%) 25 (27.8%)
IB T2a N0 M0 8 (17.4%) 27 (31.1%)
IIA T1a,b N1 M0 1 (2.2%) 0 (0%)
T2a N1 M0 0 (0%) 7 (7.7%)
T2b N0 M0 2 (4.4%) 0 (0%)
IIB T2b N1 M0 0 (0%) 2 (2.2%)
T3 N0 M0 1 (2.2%) 0 (0%)
IIIA T1-3 N2 M0 8 (17.4%) 11 (22.2%)
T3 N1 M0 1 (2.2%) 2 (2.2%)
T4 N0,1 M0 0 (0%) 2 (2.2%)
IIIB T4 N2 M0 0 (0%) 4 (4.4%)
T1-4 N3 M0 4 (8.8%) 1 (1.1%)
IV Tany Nany M1a,b 13 (28.3%) 9 (10%)
(B) TNM staging of the patients’ tumours
TNM status Stage
group
ALKþ EGFRþ p-Value
n Z 46 n Z 90
T 1a 7 (15.2%) 14 (15.6%) 0.099
1b 6 (13.0%) 12 (13.3%)
2a 21 (45.7%) 46 (51.1%)
2b 7 (15.2%) 6 (6.7%)
3 5 (10.9%) 5 (5.6%)
4 0 (0%) 7 (7.8%)
N 0 21 (45.7%) 55 (61.1%) 0.001
1 2 (4.3%) 15 (16.7%)
2 15 (32.6%) 19 (21.1%)
3 8 (17.4%) 1 (1.1%)
M 0 33 (71.7%) 81 (90.0%) 0.003
1a 3 (6.5%) 6 (6.7%)
1b 10 (21.7%) 3 (3.3%)
T: tumour status; N: nodal status; M: metastatic status.Multivariate analysis of the clinico-pathological
characteristics of ALK-positive and EGFR-positive
patients
Results of the multivariate analyses of clinico-pathological
features of ALK-positive and EGFR-positive patients are
summarized in Table 5. In accordance with earlier statis-
tical tests, the female/male ratio was lower in ALK-positive
patients (odds ratio [OR], 0.279; 95% confidence interval
[CI], 0.105e0.742) than in EGFR-positive patients, but age
was not a defining characteristic of ALK-positive patients
when compared to EGFR-positive patients. ALK-positive
patients showed more positive bronchial lesions (OR,
3215; 95% CI, 1.095e9.434), even after multivariate anal-
ysis. The fitness of this model was confirmed with the
HosmereLemeshow goodness of fitness test (p Z 0.668;
Table 5).
Discussion
Our present study population was comprised of NSCLC pa-
tients with lung adenocarcinoma who had visited a single
centre between May 2003 and June 2011. In previous
studies, the incidences of EML4-ALK fusion were approxi-
mately 5% in unselected populations of NSCLC patients
[10,11,19]. In this study, we screened lung cancer tissues by
IHC for ALK and followed with FISH for the confirmation of
ALK rearrangement as recommended by the College ofTable 4 Comparison of bronchoscopic findings of ALK- and
EGFR-positive patients.
ALKþ EGFRþ p-Value
n Z 46 n Z 90
Bronchoscopic finding 0.001
No endobronchial lesions 28 (60.9%) 78 (86.7%)
Extrinsic compression/
visible mass
18 (39.1%) 12 (13.3%)
Data are presented as n (%).
Table 5 Multivariate analysis of clinico-pathological
characteristics of ALK- and EGFR-positive patients.
Variables Adjusted
odds ratio
95% Confidence
interval
p-Value
Median age in
years (range)a
0.981 0.944e1.018 0.306
Sexb 0.279 0.105e0.742 0.011
Current/ex-smoker 0.578 0.226e1.482 0.254
Initial brain
metastasis
2.415 0.364e16.022 0.361
Positive
bronchoscopic
findings
3.215 1.095e9.434 0.033
HosmereLemeshow goodness of fit (GOF): p-Value Z 0.668.
a (xþ1 years vs. x years.)
b Odds ratio for Female/male.
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Study of Lung Cancer, and Association for Molecular Pa-
thology [20]. In our previous study, no tissues positive for
ALK rearrangement were found by FISH in 680 NSCLC cases,
with 0 in ALK-IHC and 20 cases with þ1 in ALK-IHC [17]. The
percentage of ALK-positive patients presenting with lung
adenocarcinoma, not NSCLC, was 10.4%.
We observed significant differences in demographics in
the ALK-positive patients when compared with EGFR-
positive patients in this study. ALK-positive patients had
a lower median age than EGFR-positive patients (52 vs. 64
years, respectively, p Z 0.004). A significant gender dif-
ference was also evident for ALK-positive patients (54.3%
women) in contrast with EGFR-positive patients (74.4%
women); EGFR mutations were more common in female
patients (p Z 0.021). The proportion of never-smokers
was not found to be statistically different between the 2
groups (56.5% in ALK-positive and 56.7% in EGFR-positive,
p Z 1.000). Koh et al. reported similar data in Korean
patients with lung adenocarcinoma. ALK-positive patients
were significantly younger than EGFR-positive patients
and those with wild type adenocarcinoma, with no sta-
tistically significant differences in gender or smoking
status [9].
In the initial cancer staging following diagnosis, the
tumour status was not statistically different between the 2
groups (p Z 0.099); however, the node status (p Z 0.001)
and metastatic status (p Z 0.003) were more advanced in
the ALK-positive patients. This suggests that ALK-positive
adenocarcinoma is detected in an advanced stage. An
initial status of stage IV metastatic cancer was more
frequently found in ALK-positive patients than in EGFR-
positive patients (28.3% vs. 10%, respectively, p Z 0.012).
We subsequently found that initial brain metastasis was
also significantly different according to ALK and EGFR sta-
tus (15.2% vs. 2.2%, respectively, pZ 0.007). This finding is
consistent with previous report [21].
Even though many studies have described the clinico-
pathological characteristics of ALK-positive patients
[9,11,14,22], initial bronchoscopic findings according to the
gene status of ALK- and EGFR-positive patients were first
defined in this study. ALK-positive patients weresignificantly more likely than EGFR-positive patients to
have positive bronchoscopic findings in both univariate and
multivariate analyses. This finding is the most clinically
important finding in this study. Positive bronchoscopy
findings (visible tumour or extrinsic compression) in ALK-
positive patients indicated that the origin of the ALK-
positive tumours was more centralized than that of EGFR-
positive tumours, even though both groups consisted of
adenocarcinomas that are traditionally known as peripheral
tumours rather than squamous cell or small cell carcinomas
[23,24]. The reasoning as to why ALK-positive patients
present with more positive findings in bronchoscopy should
be determined through a future study with radiologic and
pathologic examinations and we are planning the separate
study to confirm the central nature of ALK fusion-positive
tumours by examining the radiographic features of these
lung cancers.
There are limitations in the present cohort study. This is
a single centre study, and only patients with adenocarci-
noma who underwent bronchoscopy and genetic evaluation
were included, resulting in selection bias. However, we
applied bronchoscopy in almost all lung cancer patients
receiving diagnostic procedures, including chest CT and
PET-CT. Furthermore, EGFR mutation and ALK-IHC analysis
were conducted in all adenocarcinoma samples, regardless
of TNM staging. Molecular testing guidelines for EGFR and
ALK encourage molecular testing for EGFR and ALK in the
early stages of lung adenocarcinoma as an expert consensus
opinion [20] and our team has a lot of experience for mo-
lecular analysis for EGFR and ALK. Therefore, selection bias
should be minimal.
In conclusion, the EML4-ALK fusion defines a new mo-
lecular subset of adenocarcinoma with distinct clinical
and bronchoscopic findings. ALK-positive patients are
relatively younger and more often men than EGFR-positive
patients. In contrast to adenocarcinomas harbouring EGFR
mutations, ALK-positive tumours exhibited a greater
metastatic ability, particularly with regard to brain
metastasis. Moreover, ALK-positive patients had more
positive bronchoscopic findings than EGFR-positive pa-
tients, which suggested a more proximal origin. Further
study must be performed to define the reasons for these
findings.Disclosure
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